Alamar Biosciences, Inc. (NASDAQ:ALMR) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Alamar Biosciences, Inc. (NASDAQ:ALMR) have received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $30.00.

A number of research firms recently commented on ALMR. Leerink Partners began coverage on Alamar Biosciences in a research report on Tuesday, May 12th. They issued an “outperform” rating and a $35.00 target price on the stock. Zacks Research upgraded Alamar Biosciences to a “hold” rating in a research report on Wednesday, May 13th. Wall Street Zen upgraded Alamar Biosciences to a “hold” rating in a research report on Saturday, April 25th. Bank of America began coverage on Alamar Biosciences in a research report on Tuesday, May 12th. They issued a “neutral” rating and a $27.00 target price on the stock. Finally, Stifel Nicolaus began coverage on Alamar Biosciences in a research report on Tuesday, May 12th. They issued a “buy” rating and a $28.00 target price on the stock.

Alamar Biosciences Stock Down 4.4%

Shares of Alamar Biosciences stock opened at $20.54 on Friday. Alamar Biosciences has a one year low of $18.84 and a one year high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last announced its quarterly earnings data on Friday, May 8th. The company reported ($1.74) earnings per share (EPS) for the quarter. The firm had revenue of $26.04 million for the quarter.

Insider Activity

In other news, Director Nicholas Naclerio acquired 235,294 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was acquired at an average price of $17.00 per share, with a total value of $3,999,998.00. Following the completion of the purchase, the director directly owned 507,076 shares in the company, valued at approximately $8,620,292. This trade represents a 86.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Innovation Fund Gp Illumina II bought 235,294 shares of the business’s stock in a transaction dated Monday, April 20th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $3,999,998.00. Following the purchase, the insider owned 507,076 shares of the company’s stock, valued at approximately $8,620,292. The trade was a 86.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.